JP Morgan Chase
CNTX icon

JP Morgan Chase’s Context Therapeutics CNTX Stock Holding History

JP Morgan Chase’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.3K Buy
38,621
+28,199
+271% +$57.2K ﹤0.01% 6702
2026
Q1 		$25.5K Buy
+10,422
New +$24.3K ﹤0.01% 6460
2025
Q2 		– Sell
-80
Closed -$49 – 7154
2025
Q1 		$49 Sell
80
-86
-52% -$75 ﹤0.01% 6987
2024
Q4 		$174 Sell
166
-7
-4% -$12 ﹤0.01% 6928
2024
Q3 		$339 Buy
+173
New +$384 ﹤0.01% 6841
2024
Q2 		– Sell
-33
Closed -$46 – 7399
2024
Q1 		$46 Buy
33
+10
+43% +$11 ﹤0.01% 7055
2023
Q4 		$26 Buy
23
+7
+44% +$8 ﹤0.01% 7300
2023
Q3 		$24 Buy
+16
New +$18 ﹤0.01% 7131

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

JP Morgan Chase's CNTX Position: Q2 2026 in Review

JP Morgan Chase increased its Context Therapeutics (CNTX) stake by 271% in Q2 2026, buying an estimated $57.2K and bringing the position to 38,621 shares worth $22.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6702.

JP Morgan Chase first reported a position in CNTX in Q3 2023 and has held it in 8 quarters since. The position peaked at $25.5K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • JP Morgan Chase held 38,621 shares of Context Therapeutics worth $22.3K as of Q2 2026.
  • JP Morgan Chase bought 28,199 Context Therapeutics shares in Q2 2026, an estimated $57.2K.
  • Context Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6702 holding.
  • JP Morgan Chase first reported a position in Context Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • JP Morgan Chase's Context Therapeutics position peaked at $25.5K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.